Therapeutic Specific Areas

Merck and Mestag Therapeutics Partner on Inflammatory Diseases in $1.9 Billion Collaboration

October 17, 2024

Through the collaboration, Merck will use Mestag’s proprietary RAFT platform to investigate the pathogenic role that fibroblasts play in inflammatory diseases.

FDA Approval of Lilly's EBGLYSS Provides New Treatment for Atopic Dermatitis

September 23, 2024

By approving EBGLYSS (lebrikizumab-lbkz), FDA has made available a new biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topical treatments.

Lilly Completes $3.2 Billion Acquisition of Morphic, Boosting Its IBD Pipeline

August 27, 2024

With the completion of its acquisition of Morphic, Lilly expands its immunology pipeline to include Morphic's oral integrin therapies to address inflammatory bowel disease.

AstraZeneca Strengthens Rare Disease Portfolio with Amolyt Pharma Acquisition

July 18, 2024

The acquisition adds a Phase III therapeutic peptide candidate to AstraZeneca’s late-stage pipeline for rare diseases.

Johnson & Johnson Completes Numab Subsidiary Acquisition, Boosts Bispecific Antibody Pipeline

July 16, 2024

The acquisition adds NM26, a Phase II-ready bispecific antibody for treating atopic dermatitis, to Johnson & Johnson’s immune-mediated and inflammatory disease portfolio.

Pfizer Teams up with Evotec on Drug Discovery

July 11, 2024

Through a multi-year collaboration, Pfizer and Evotec aim to conduct early discovery research for therapeutics against metabolic and infectious diseases.

AbbVie Acquires Celsius Therapeutics, Gains Anti-Inflammatory Disease Antibody

June 28, 2024

The Celsius Therapeutics acquisition will add CEL383, a potential first-in-class anti-TREM1 antibody for IBD, to AbbVie’s portfolio.

FDA Expands Approval of Sarepta’s Duchenne Muscular Dystrophy Gene Therapy

June 25, 2024

FDA has granted expanded approval to Sarepta Therapeutics for Elevidys to treat DMD in non-ambulatory patients, in addition to ambulatory patients.

Johnson & Johnson Pursues Global Rights to Numab Therapeutics’ AD-Targeting Bispecific Antibody in $1.25 Billion Acquisition

May 29, 2024

Under an agreement, Johnson & Johnson will acquire Numab Therapeutics’ wholly owned subsidiary to gain global rights to NM26, a bispecific antibody targeting atopic dermatitis.

Biogen Boosts Immunology Portfolio with $1.8 Billion Acquisition of HI-Bio

May 23, 2024

Biogen’s acquisition of HI-Bio includes lead investigational mAb, felzartamab, under development for treating a range of immune-mediated diseases.